2023年 3 月85

9The 12th International Forum of The Japanese Society of Gastroenterology
DAY2Time ＆ Date：9：00～18：10, Friday, April 7, 2023
Place：Room 6（1F, Conference Room 101-AB）
Main Theme：Therapeutic advances in gastrointestinal and hepatobiliary-pancreatic cancers（Current medical management of gastrointestinal and hepatobiliary-pancreatic cancers）
1. Esophageal cancer（9：00～10：10）
Moderator：Manabu Muto（Department of Clinical Oncology, Kyoto University, Japan）
IF1-1

IF1-2

IF1-3

3D organoid system and a novel esophageal cancer cell-specific vulnerability
Hiroshi Nakagawa（Columbia University Digestive and Liver Diseases
Research Center, New York, USA）
Intrinsic molecular subtype and prediction of response to chemoradiotherapy inesophageal cancer
Manabu Muto（Department of Therapeutic Oncology, Graduate School ofMedicine, Kyoto University, Japan）
Immuno-Oncology for esophageal cancer：updated in 2023
Ken Kato（Department of Head and Neck, Esophageal Medical Oncology,
National Cancer Center Hospital, Japan）

IF2-1
IF2-2

IF2-3

IF2-4

The clinical application of“Liquid Biopsies”in the search of molecular targets
Tanios Bekaii-Saab（Mayo Clinic, U.S.A.）
SCRUM-Japan Initiatives for Precision Oncology
Hideaki Bando（Translational Research Support Office, Division of Drug andDiagnostic Development Promotion, Department for thePromotion of Drug and Diagnostic Development, NationalCancer Center Hospital East, Japan）
ctDNA and minimal residual disease detection in resectable colorectal cancer
Jeanne Tie（Department of Medical Oncology, Peter MacCallum Cancer
Centre, Melbourne, Australia）
The CIRCULATE-JAPAN：Nationwide large-scale clinical trial for circulatingtumor DNA-guided management for colorectal cancer
Eiji Oki（Department of Surgery and Science, Graduate School of MedicalSciences, Kyushu University, Japan）

The 12thInternational Forum

2. Latest Precision Oncology in Colorectal Cancer（10：20～11：30）
Moderator：Takayuki Yoshino（Department of Gastroenterology and Gastrointestinal Oncology,National Cancer Center Hospital East, Japan）

1086

日本消化器病学会雑誌

第120巻臨時増刊号

3. Challenge for clinical issues in systemic therapy for hepatocellular carcinoma（14：20～15：30）
Moderator：Masafumi Ikeda（Department of Hepatobiliary ＆ Pancreatic Oncology, NationalCancer Center Hospital East, Japan）
IF3-1

IF3-2

IF3-3

IF3-4

Biomarker-based precision systemic therapy for advanced HCC
Takahiro Kodama（Department of Gastroenterology and Hepatology, Osaka
University Graduate School of Medicine, Japan）
Current status and emerging issues of systemic therapy in patients withadvanced hepatocellular carcinoma from Japanese real world practice
Sadahisa Ogasawara（Department of Gastroenterology, Graduate School ofMedicine, Chiba University, Japan）
Potential different immunotherapy efficacy among different etiology of HCC：
are we ready to select regimens per etiology?
Changhoon Yoo（Department of Oncology, Asan Medical Center, University of
Ulsan College of Medicine, Seoul, Korea）
Grow from mistakes―perspective of systemic therapy for HCC
Ann-Lii Cheng（Department of Medical Oncology, National Taiwan University
Cancer Center, Taiwan）

4. Interventional EUS for pancreatobiliary diseases（15：40～16：50）
Moderator：Ichiro Yasuda（Third Department of Internal Medicine, University of Toyama,Japan）
IF4-1
The 12th
International Forum

IF4-2

IF4-3

IF4-4

Interventional EUS for pancreatobiliary diseases
Marc Giovannini（Paoli-Calmettes Institute, 232 Bd St-Marguerite 13273
Marseille cedex 9, France）
Techniques and outcomes of EUS-guided gastroenterostomy
Anthony YB Teoh（Department of Surgery, The Chinese University of HongKong, Hong Kong, SAR）
Technical tips for endoscopic ultrasound-guided biliary drainage to prevent
adverse event and improve technical success rate
Takeshi Ogura（Endoscopy Center, Osaka Medical and Pharmaceutical
University Hospital, Osaka, Japan）
EUS-guided Celiac Plexus and Celiac Ganglia Neurolysis in Pancreatic Cancer
Shinpei Doi（Department of Gastroenterology, Teikyo University Mizonokuchi
Hospital, Japan）

2023年 3 月

8711

5. Topics of PRRT tratment for pancreatic gastrointestinal neuroendocrine tumors（17：00～18：10）
Moderator：Tetsuhide Ito（Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital, Japan）
IF5-1

IF5-2IF5-3

Predictive Factors for Resistant Disease with PRRT in Patients with Advanced
Pancreatic Neuroendocrine Neoplasms
Lingaku Lee（Department of Hepato-Biliary-Pancreatology, National Hospital
Organization Kyushu Cancer Center, Fukuoka, Japan.）
Peptide Receptor Radionuclide Therapy for Unresectable
Gastroenteropancreatic Neuroendocrine Tumors
Noritoshi Kobayashi（Department of Oncology, Yokohama City University
Graduate School of Medicine, Japan）
TBA
Current
status and future strategies for the treatment of advanced

gastroenteropancreatic neuroendocrine neoplasms
Nao Fujimori（Department of Medicine and Bioregulatory Science, GraduateSchool of Medical Sciences, Kyushu University）

The 12thInternational Forum